Clinical trial · no report yet · Phase 2
NCT06437509
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer
- NCT06437509 ↗
- Recruiting
- Sichuan Baili Pharmaceutical Co., Ltd.
- 3 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built. Commentary is thin so far, so the report would be short.
| Channel | Found | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase II Clinical Trial to Evaluate the Efficacy and Safety of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Extensive-stage Small-cell Lung Cancer
- Interventions
- BL-B01D1; PD-1 monoclonal antibody
- Arms
- Study treatment · Experimental
- Enrollment
- 66 (estimated)
- Primary outcomes
- Objective Response Rate (ORR)
- Recommended Phase II Dose (RP2D)
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd. with Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
- Start
- Jun 13, 2024
- Primary completion
- Dec 2026 (estimated)
- Results posted
- No
- Registry record
- NCT06437509 · updated Jul 23, 2026